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| INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolysis disorder that results from uncontrolled complement system activation and causes hemolytic anemia and marrow failure. Infection and thrombosis are also severe complications of PNH, which can be life-threatening. Administration of eculizumab, a complement inhibitor of C5, during pregnancy has been reported useful in improving maternal and fetal outcomes in patients with PNH. 1 However, the need for peripartum dose adjustment is rarely discussed. We herein report a case of a patient with PNH who underwent two cesarean deliveries under eculizumab treatment and discuss the necessity of eculizumab peripartum dose adjustment.
| CASE PRESENTATION
A 34-year-old primipara woman was diagnosed when she was 18 years with PNH, which started with symptom of hematuria and anemia. Anemia was under control by iron agents without transfusion. There was no episode of thrombosis. However, she was diagnosed with asymptomatic primary biliary cholangitis at 33 years and received her first eculizumab treatment for hemolysis at 34 years, which started with a loading dose of 600 mg once a week and was subsequently increased to 900 mg every 2 weeks. The response to eculizumab was good. Three months later, she was found to be pregnant. Administration of eculizumab, 900 mg every 2 weeks, was continued, and she had no episode of hemolysis during pregnancy. At gestational week 39, she was hospitalized due to fetal growth restriction (FGR). Labor was induced by oxytocin at week of 40, but an emergency cesarean section was required due to abnormal fetal heart rate (late deceleration). A healthy 2775-g male infant with Apgar score of 7/9 at 1/5 minutes was delivered. On postoperative day 5, the patient's C-reactive protein (CRP) increased to 10.2 mg/dL and her lactate dehydrogenase (LDH) increased to 637 IU/L, which revealed hemolysis. Thus, the patient was administered 5000 units of heparin subcutaneously twice daily for 6 weeks and 900 mg of eculizumab every 2 weeks. After the treatment, hemolysis was controlled. Two years later, a second pregnancy was detected during eculizumab treatment. The pregnancy course was uneventful, with no hemolysis observed. With the patient's history of postoperative hemolysis, preoperative administration of eculizumab was given 1 day just before her cesarean section. At gestational week 37, a cesarean section was performed and a healthy female baby with Apgar score of 8/9 was delivered. Subsequently, eculizumab and 6 weeks of subcutaneous heparin were administered postpartum; no evidence of hemolysis was found (Figure 1 ).
| DISCUSSION
Eculizumab is a monoclonal antibody that binds to complement C5, inhibiting the formation of the C5-9 terminal complement complex that attacks the membrane of red blood cells. Eculizumab has a half-life of 4-21 days 2 and is metabolized into small peptides and amino acids by lysosomal enzymes. Nakayama et al 3 retrospectively analyzed 763 doses in 14 patients with PNH and concluded that prolonged dosing intervals of 17 days or more may be associated with the development of breakthrough hemolysis (LDH >1000 U/L). A 50% hemolytic complement (CH50) activity and evaluated LDH levels are strongly associated with circulating free eculizumab. 4 These parameters can also predict postoperative infection and hemolysis. LDH is one of the easily measured parameters when monitoring patients with PNH on eculizumab. 3, 5 The shortened interval or increased dosage is recommended if hemolysis occurred. 4 Operative invasion, trauma, and anesthesia are factors that activate the complement system, 6 resulting in surgerytriggered hemolysis. Postoperative complement system activation is also associated with inflammatory response 7 as well as alternative pathway through bacterial invasion. Therefore, postoperative complement system activation is a major concern during postoperative management of patients with PNH. Successful preoperative administration of eculizumab to prevent postoperative hemolysis has been reported in other surgeries, for example, in cardiopulmonary bypass. 8 In obstetrics, eculizumab given before cesarean section has been described in a patient with severe antiphospholipid syndrome. 9 However, very few similar discussions in obstetrics are reported. Previously, before eculizumab was available, pregnancy was not recommended in patients with PNH. The mortality rate of pregnant women with PNH is 8%-20%, and hepatic venous thrombosis (Budd-Chiari syndrome) was known as a major cause of maternal death. 10 In addition, cases of hemolytic crisis (28%), thrombosis (14%), and hemorrhage (mainly cerebral, 14%) are highly common in pregnancy. The rate of fetal wastage is as high as 30%, mostly due to abortion. 10 After eculizumab became available, maternal and fetal prognosis has improved. Kelly et al 1 investigated 61 pregnant women with PNH from 31 institutes in 9 countries and observed that the maternal survival rate was 100%, with live birth rate of 92%, when eculizumab was given. Even with a preterm labor rate as high as 29% and the risk of preeclampsia and FGR, which are the most common reasons for requiring termination, the long-term prognosis of the offspring is very good. 1 In terms of effects on the fetus, despite the presence of eculizumab in umbilical blood, 11 no suppression of complement system was found in newborn babies. 12 Therefore, eculizumab administration is considered safe during pregnancy. An increase in soluble fms-like tyrosine kinase 1 (sFLT-1) in maternal serum may account for ischemic placental disease such as HELLP/preeclampsia/FGR, 13, 14 and eculizumab administration decreases sFLT-1. Burwick and Feinberg 15 reported a case of severe preeclampsia/HELLP syndrome that was treated with eculizumab, which led to a temporary normalization of the patient's laboratory parameters and to prolongation of gestational from 26 to 29 weeks. Conversely, 50% (11/22) of chronic renal failure patients with PNH had improved symptoms after eculizumab administration. 16 Although eculizumab contributes to the prevention of hemolysis, preeclampsia, and renal failure, it is rapidly metabolized by activated lysosomes as pregnancy progresses. Approximately 54% of patients with PNH need increased dose of eculizumab for the treatment of hemolysis. 1 To date, the appropriate timing to increase eculizumab during pregnancy has not been well discussed. In the present case, we observed that administration of eculizumab 1 day just before cesarean section prevented postoperative hemolysis. Hence, we believe that elective cesarean section should be performed soon after routine eculizumab infusion, or an extra dose to shorten the interval between eculizumab infusion and cesarean section should be considered to help prevent postoperative hemolysis. Further research is required to verify the results observed for our case. 
